Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Discovery of intermolecular cascade annulation for dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones

Wenjun Luo *a, Xinghua Zheng a, Hehua Lin a, Li Fu b, Lipeng Long a, Daohong Yu a, Zhengwang Chen a, Min Yang *b and Zhong-Xia Wang *a
aJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou 341000, P. R. China. E-mail: wenjunluo@gnnu.edu.cn; zhongxiawang@ncu.edu.cn
bSchool of Pharmacy, Jiangxi Provincial Key Laboratory of Tissue Engineering, Gannan Medical University, Ganzhou 341000, China. E-mail: min_yang100@163.com

Received 26th November 2024 , Accepted 22nd January 2025

First published on 28th January 2025


Abstract

Developing efficient procedures for the synthesis of combinations of pharmacophores continues to be a vital objective in synthetic science. Herein, we report an unprecedented family of dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones achieved by reacting ortho-halogenated quinolonechalcones with aminomaleimides under metal-free conditions. Among these compounds, several exhibit the potential to serve as fluorescent dyes for biological applications. Mechanistic investigations indicate that the reaction proceeds via a 1,4-Michael addition followed by an intermolecular cascade annulation, which involves aniline fragment transfer and SNAr processes. As far as we know, studies regarding the synthesis of dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones are rare. This discovery offers great inspiration for a feasible approach toward the creation of more complex and useful molecules.


Introduction

Pyrrolidine-2.5-dione and dihydrobenzo[b][1,8]naphthyridine derivatives, as significant nitrogen-containing heterocyclic compounds, are widely found in pharmaceutical molecules.1,2 For example, pyrrolidinetrione derivatives (I) have functioned as antifungal agents that effectively resist potato diseases.3 Tivantinib (II) acts as a highly selective inhibitor of the c-Met tyrosine kinase.4 The dihydrobenzo[b][1,8]naphthyridine compound RP60556A (III) shows activity in resisting multidrug-resistant Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), and demonstrates potential in vivo efficacy as an acetylcholine esterase inhibitor.5 Compound VI, known as eucophylline, is part of the dihydrobenzo[b][1,8]naphthyridine series (Fig. 1).6
image file: d4sc07999j-f1.tif
Fig. 1 The significance of pyrrolidine-2.5-diones and dihydrobenzo[b][1,8]naphthyridine derivatives.

Developing efficient procedures for synthesizing combinations of pharmacophores remains a crucial objective in synthetic organic chemistry.7 Consequently, our interest lies in investigating novel strategies or methodologies to synthesize dihydrobenzo[b][1,8]naphthyridines fused with pyrrolidinediones, which could represent promising and innovative approaches in the field of drug discovery. According to the literature, various methodologies for preparing pyrrolidine-2.5-diones8 and dihydrobenzo[b][1,8]-naphthyridine derivatives9 from easily available materials have been well established. It is widely known that aminomaleimides can attack electrophiles at two positions: the carbon atom of the C[double bond, length as m-dash]C group10 and the N-group11 substituted at the 3-position. As illustrated in Scheme 1b: (a) when reacting with a monoelectrophilic reagent, two or more distinct products may potentially form. (b) With an amphiphilic electrophilic reagent, one possible pathway involves reactions at the C-4 position and the N site substituted at the 3-position, leading to the formation of cyclized products.12


image file: d4sc07999j-s1.tif
Scheme 1 Transformations of aminomaleimides and ortho-halogenated quinolinechalcones: (a) this work: the actual reaction process; (b) reactivity of aminomaleimides; (c) reactivity of ortho-halogenated quinolinechalcones; (d) designed pathway.

Similarly, ortho-halogenated quinolonechalcones can undergo nucleophilic attacks at three positions: the carbon atom of the C[double bond, length as m-dash]O group, the β-carbon of the C[double bond, length as m-dash]C bond, and the C2′-quinoline site.13 These three active centers are all electron-deficient, making them susceptible to nucleophilic attack. As illustrated in Scheme 1c: (a) when reacting with a mononucleophilic reagent, three or more distinct products may potentially form.14 (b) With an amphiphilic nucleophilic reagent, one possible pathway involves reactions at the C1 and C3 sites, leading to the formation of cyclized products.15 Another pathway may involve reactions at the C2′ and C3 sites, also yielding cyclized products, or additional reaction pathways may exist.16

Building on our previous work,17 we envision that the equilibrium of aminomaleimides indicates its potential as a suitable synthon in the proposed annulation. By using ortho-halogenated quinolonechalcones 1, which contain a Michael acceptor and a chlorine or bromine leaving group at the ortho-position of the quinoline ring, the expected dihydrobenzo[b][1,8]naphthyridines fused with pyrrolidinediones 3′ or 3′′ could be readily achieved (Scheme 1d). However, we did not obtain the anticipated products. Based on previous developments,18 cascade annulation reactions have emerged as a useful strategy for preparing complex molecular structures, especially in metal-free reactions.19 We discovered that the reaction unexpectedly proceeded via a 1,4-Michael addition followed by an intermolecular cascade annulation, resulting in the formation of dihydrobenzo[b][1,8]naphthyridines fused with pyrrolidinetrione, compound 3, under metal-free conditions (Scheme 1a). Hopefully, this work has also been highlighted through gaining valuable insights into fluorescent dyes for potential biological applications.

Initially, we investigated the reaction between 3-((4-bromophenyl)amino)-1-ethyl-1H-pyrrole-2,5-dione 1a and (E)-1-phenyl-3-(phenylamino)prop-2-en-1-one (2a, 2.0 equiv.) in the presence of 1.5 equivalents of cesium carbonate (Cs2CO3) in ethanol at reflux for 12 hours (Table 1). To our delight, the unexpected product (E)-4-(1-(4-bromophenyl)-2-phenylbenzo-[b][1,8]naphthyridin-4(1H)-ylidene)-1-ethylpyrrolidine-2,3,5-trione 3a was obtained in 26% yield (entry 1). Subsequently, various bases were screened (K2CO3, Na2CO3, Et3N, DBU, and DABCO, entries 2–8), but none provided better results than Cs2CO3. The solvent effect was also investigated, and the results showed that N,N-dimethylformamide (DMF) proved to be the best choice, furnishing the desired product 3a in 70% yield (entries 9–15). Next, the addition of oxidizing additives did not lead to the detection of 3a (entries 16–19). When ‘Br’ was substituted for ‘Cl’ at C-2′ in substrate 2a, product 3a was also attained (entry 20). Additionally, decreasing the reaction temperature to 60 °C or replacing cesium carbonate with potassium carbonate failed to provide good yields (Table 1, entries 21 and 22). Consequently, the optimal reaction conditions were identified as using Cs2CO3 as the base and DMF as the solvent at 80 °C.

Table 1 Optimization of reaction conditionsa,b

image file: d4sc07999j-u1.tif

Entry Base Additive Solvent Temp (°C) Yieldb (%)
a Reaction conditions: 1a (0.1 mmol) and 2a (0.2 mmol) were reacted at reflux or 80 °C in the presence of base (0.15 mmol) in 2 mL of the solvent in air. b Isolated yields. n.d. = not detected. c ‘Cl’ at C-2′ of 2a instead with ‘Br’.
1 Cs2CO3 EtOH Reflux 26
2 K2CO3 EtOH Reflux 15
3 Na2CO3 EtOH Reflux Trace
4 Et3N EtOH Reflux Trace
5 DBU EtOH Reflux Trace
6 DABCO EtOH Reflux Trace
7 Piperidine EtOH Reflux n.d.
8 PPh3 EtOH Reflux n.d.
9 Cs2CO3 MeOH Reflux 12
10 Cs2CO3 EA Reflux 10
11 Cs2CO3 Toluene 80 20
12 Cs2CO3 THF Reflux 48
13 Cs2CO3 DMSO 80 44
14 Cs 2 CO 3 DMF 80 70
15 Cs2CO3 CH3CN 80 30
16 Cs2CO3 DDQ DMF 80 n.d.
17 Cs2CO3 K2S2O8 DMF 80 n.d.
18 Cs2CO3 BPO DMF 80 Trace
19 Cs2CO3 IBX DMF 80 Trace
20c Cs2CO3 DMF 80 68
21 Cs2CO3 DMF 60 45
22 K2CO3 DMF 80 40


Using the optimal reaction conditions, we began to evaluate the scope of various aminomaleimides 1 with (E)-1-phenyl-3-(phenylamino)prop-2-en-1-one 2a (Scheme 2). It was observed that aminomaleimides bearing electron-rich at the N-3 position aryl groups reacted more favorably compared to those with electron-deficient substituents. Specifically, N-4-methoxyphenyl-substituted aminomaleimides yielded product 3g in 74% yield, while the N-4-(trifluoromethyl)phenyl-substituted analogs provided product 3i with a lower yield of 42%. The substituent position on the N-aryl group of acyclic enaminone significantly influences the reaction results. Both meta-substituted (3l–3q) and ortho-substituted (3r–3t) aminomaleimide substrates with N-aryl groups produced the target compounds, albeit with reduced yields. Aminomaleimides featuring disubstituted and trisubstituted aryl groups at the N-3 position also demonstrated effectiveness, generating products 3u–3w in 56–60% yield. Moreover, substrates with 1-naphthyl and benzo[d][1,3]dioxol-5-yl substitutions at the N-3 position yielded the target compounds at 70% (3x) and 47% yield (3y), respectively. Notably, benzene rings substituted at the 4-position with a carbazole or N,N-dimethylphenyl group exhibited good compatibility, resulting in the respective products with 45% (3z) and 46% yield (3aa). It is noteworthy that aminomaleimides, which feature ortho-chiral oxazole-substituted groups at the benzene rings 1ab, resulted in a 1[thin space (1/6-em)]:[thin space (1/6-em)]1 diastereoisomeric mixture of 3ab with a yield of 38%. This outcome is likely attributed to their asymmetrical structure and the steric hindrance imposed by the ortho-substituted aminomaleimide. Such structural features lead to C–N axis chirality and the presence of racemic atropisomers in their configurations. Additionally, aminomaleimides derived from naphthalene-1,5-diamine (1ac) and the reaction with bis-molecular ortho-chloroquinolinechalcone 2a yielded the desired product 3ac with a 30% yield. Encouragingly, replacing the benzene ring with ethyl led to corresponding products in 52% yield (3ad), while adamantane substitution failed to produce the desired 3ae product, possibly due to significant steric hindrance.


image file: d4sc07999j-s2.tif
Scheme 2 Scope of the substrates.a,b a Reaction conditions: 1 (0.1 mmol) and 2 (0.2 mmol), and Cs2CO3 (0.15 mmol) in DMF (2.0 mL) at 80 °C for 12 h in air. b Yield was determined after the product was purified by silica-gel chromatography. c Determined by 1H NMR analysis. c1ac (0.1 mmol) and 2a (0.4 mmol).

Additional functional group compatibility and substrate scope were examined by varying the substituents at the N-1 positions of aminomaleimides. Substrates carrying benzyl (3af), phenyl (3ag), (R) or (S)-2-hydroxypropyl (3ah), and hydroxyethyl (3ai) groups on nitrogen were well tolerated. Next, the effect of substituents on the quinoline ring of ortho-chloroquinolinechalcones 1 was investigated. Substituents including fluorine and methyl groups on the quinoline ring were compatible with aminomaleimide 2a, facilitating the synthesis of the corresponding products in moderate yields (51% and 60%) (3aj and 3ak). Furthermore, disubstituted aromatic rings and those containing a 1-naphthalene group on the quinoline moiety also produced cyclization products efficiently, with yields between 55% and 64% (3al–3an). Surprisingly, ortho-chloroquinolinechalcones 1a with a methyl substitution on the phenyl group could still afford the desired products with a 45% yield (3ao). However, ortho-chloroquinolin-α,β-unsaturated esters (2h and 2i) failed to produce the expected product, which may be attributed to the ester group being less reactive than the ketone. To broaden the chalcone varieties, 2-halopyridinechalcones 6a and 6b were subjected to testing. The identical target product 7a was successfully obtained, with yields of 14% (for 2-Cl) and 23% (for 2-F), respectively (for more details see S38 and S39 in the ESI). Additionally, the structure of compound 3 was confirmed by X-ray diffraction analysis of 3a (CCDC 2390992).20

To gain a deeper understanding of the reaction mechanism, we designed and conducted a series of control experiments. First, to investigate whether the cleavage and reformation of the aniline fragment during the reaction is an intramolecular process, we conducted the following experiments (Scheme 3): (a) compound 1a was treated under standard conditions, and p-bromoaniline was successfully detected as a product. However, when an additional 2a was added to this system, the expected formation of target product 3a was not observed. (b) We attempted to react 2a directly with p-bromoaniline under the same standard conditions, but the desired product, where the aniline substitutes for the chlorine atom, was not obtained. (c) We investigated whether a cross-reaction would occur between 1a and 2a in the presence of p-anisidine. Despite the introduction of p-anisidine, the final product remained 3a, indicating that the expected cross-reaction did not take place. To further confirm this, we added aniline to the reaction mixture of 1g and 2a, and the experimental results showed that the only product formed was 3g (for more details see S38 and S39 in the ESI). These experiments collectively demonstrate that the reformation of the aniline fragment in this reaction occurs strictly through an intramolecular mechanism. Next, to further elucidate the specific pathway of the reaction, we conducted experiments using 1a and 2a in dichloromethane as the solvent, at room temperature, with Cs2CO3 (1.5 equiv.) as the base. From this setup, we successfully isolated intermediate 4a. Detailed nuclear magnetic resonance (NMR) analysis, including 1H-NMR, 13C-NMR, and two-dimensional NMR spectra, along with high-resolution mass spectrometry (HRMS), confirmed that the reaction initially underwent a Michael addition step, forming intermediate 4a (for more details see S40–S48 in the ESI). Subsequently, submitting the obtained 4a to the standard reaction conditions allowed us to achieve the final target product 3a (Scheme 3d). This process further validated our understanding of the reaction pathway. The structures of the reactant and the product suggest that one molecule of water might be incorporated into the reaction system. Therefore, the role of water in the reaction was investigated. Interestingly, upon the addition of 3.0 equiv. of H18O to the unproductive anhydrous reaction system, the mixture of 18O-labeled and the normal dihydrobenzo[b][1,8]naphthyridines fused with pyrrolidinetrione product 3b was detected (Scheme 3e). This result demonstrated that a small amount of water participates in the reaction.


image file: d4sc07999j-s3.tif
Scheme 3 Control experiments: (a) only compound 1a treated under standard conditions; (b) compound 2a directly react with p-bromoaniline under the standard conditions; (c) cross-over tested; (d) isolated intermediate; (e) H218O used.

Considering that commercial solvent was used directly without drying, we hypothesized a plausible reaction mechanism as shown in Scheme 4. Initially, aminomaleimides 1 and ortho-chloroquinolinechalcones 2a undergo Michael addition, leading to the formation of intermediate I, which can undergo tautomerism and transform into 4. Subsequently, water attacks the imine structure of intermediate I, giving the resulting amine which undergoes a synergistic intramolecular addition-transfer-reaction with the carbonyl group of the chalcone, forming six-membered cyclic intermediate II by a series of imine/hemiaminal formations and a hydrolysis process occurs to form intermediate III, which further tautomerizes and transforms into intermediate IV. An intramolecular SNAr substitution ultimately takes place, resulting in the formation of intermediate V, which then undergoes rotation and oxidation to yield the final product 3.


image file: d4sc07999j-s4.tif
Scheme 4 Proposed reaction mechanism.

Among these dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones, we were surprised to find that 3d, 3g, 3k, 3l, 3n, 3r, 3v, 3ag and 3ak showed significant photophysical properties. As part of a program for developing some multifunctional dyes in biological processes,21–28 we evaluated their photophysical properties in six selected organic solvents with different properties (DMSO, EtOH, toluene, 1,4-dioxane, DCM, and PBS) via a multiwell analysis method. The results revealed that these compounds showed different spectral characteristics in different solvents, such as the fluorescence intensity and emission wavelength. As shown in Fig. 2, the monofluoro-substituted dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones (3d, 3n, and 3r) exhibited near-infrared photophysical properties in PBS (λex = 420 nm, λem = ∼744 nm), which provided their potential biological application. As expected, some of the dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones (3d, 3n, 3r, and 3ag) were subjected as fluorescent dyes to live human glioma U251 cell imaging, which preliminarily indicated a positive aspect in biocompatibility and low-toxicity (for more details see S79–S84 in the ESI). Further biological applications will be reported in due course.


image file: d4sc07999j-f2.tif
Fig. 2 Live human glioma U251 cell imaging after 4 h of incubation: (a) FITC channel: λex = 488 nm; (b) bright field; (c) merged image.

Conclusions

In summary, we have disclosed a promising approach for developing a novel family of dihydrobenzo[b][1,8]naphthyridine-ylidene-pyrrolidinetriones through the fusion of aminomaleimides and quinoline chalcones. The reaction mechanism has been meticulously explored, and it proceeds via a key intermolecular cascade annulation pathway that involves aniline fragment transfer and SNAr processes. Remarkably, our discovery indicates that such an annulation approach can be carried out under metal-free conditions, while also demonstrating excellent tolerance towards functional groups and featuring operational simplicity. Moreover, several of the desired compounds have been validated as alternative fluorescent dyes by means of fluorescence spectrum analysis as well as live human glioma U251 cell imaging. These verifications have preliminarily showcased their potential for biological applications. This work offers valuable guidance for the construction of biologically active functional products, thus making significant contributions to the fields related to both chemical synthesis and biological functionality exploration.

Data availability

The data supporting this article have been included as part of the ESI.

Author contributions

W. J. and Z. Z. discovered and developed the reactions. Z. Z. and H. L. performed a portion of the synthetic experiments. L. L, D. Y. and Z. C. participated in substrate scope surveys and discussions. L. F. and M. Y. performed the biological experiments. Z.-X. W., M. Y. and W. L. directed the project and wrote the original draft (including the ESI).

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful for financial support from the National Natural Science Foundation of China (22222502, 22308061, 22461002, and 22467002), the Jiangxi Provincial Natural Science Foundation (20243BCE51174, 20242BAB20110, and 20224BAB203011), the Science and Technology Project of Jiangxi Provincial Education Department (GJJ2201224 and GJJ2201220), the Gannan Normal University Doctoral Research Initiation Fund (BSJJ202228) and the Research Team Program of Gannan Normal University. We acknowledge Dr Yu Si from the College of Traditional Chinese, Yunnan University of Traditional Chinese Medicine, for providing the 2D-NMR analysis.

Notes and references

  1. For selected pyrrolidine-2.5-dione examples, see: (a) H. Gunosewoyo, A. Midzak, I.-N. Gaisina, E.-V. Sabath, A. Fedolak, T. Hanania, D. Brunner, V. Papadopoulos and A.-P. Kozikowski, J. Med. Chem., 2013, 56, 5115 CrossRef CAS; (b) J.-T. Husband, Y.-J. Xie, T.-R. Wilks, L. Male, M. Torrent-Sucarrat, V.-G. Stavros and R.-K. O'Reilly, Chem. Sci., 2021, 12, 10550 RSC; (c) Y.-L. Xu, X.-Y. Zhou, L.-Y. Chen, Y.-F. Ma and G. Wu, Org. Chem. Front., 2022, 9, 2471 RSC; (d) Y. He, W. Li, H. Zhou, G. Zeng, Z. Chen, J. Ge, N. Lv and J. Chen, Adv. Synth. Catal., 2022, 364, 3730 CrossRef CAS; (e) S. Y. Ho, J. Alam, D. A. Jeyaraj, W. Wang, G. R. Lin, S. H. Ang, E. S. W Tan, M. A. Lee, Z. Ke, B. Madan, D. M. Virshup, L. J. Ding, V. Manoharan, Y. S. Chew, C. B. Low, V. Pendharkar, K. Sangthongpitag, J. Hill, T. H. Keller and A. Poulsen, J. Med. Chem., 2017, 60, 6678 CrossRef CAS; (f) H. T. Nguyen, H.-G. Kim, N. H. Yu, I. M. Hwang, H. Kim, Y. C. Kim and J.-C. Kim, J. Agric. Food Chem., 2021, 69, 5471 CrossRef CAS; (g) J. Needham, M. T. Kelly, M. Ishige and R. J. Andersen, J. Org. Chem., 2002, 59, 2058 CrossRef.
  2. For selected dihydrobenzo[b][1,8]naphthyridine examples, see: (a) K. Yoshiaki, F. Hiroshi, N. Shieyoshi, N. Izumi and T. Haruko, EP0430485A2, 1991; (b) D. Mabire, S. Coupa, C. Adelinet, A. Poncelet, Y. Simonnet, M. Venet, R. Wouters, A. S. J. Lesage, L. V. Beijsterveldt and F. Bischoff, J. Med. Chem., 2005, 48, 2134 CrossRef CAS; (c) J. Deguchi, T. Shoji, A. Nugroho, Y. Hirasawa, T. Hosoya, O. Shirota, K. Awang, A. Hadi and H. Morita, J. Nat. Prod., 2010, 73, 1727 CrossRef CAS; (d) A. Weyesa and E. Mulugeta, RSC Adv., 2020, 10, 20784 RSC; (e) Y. Yue, T. Zhao, Y. Wang, K. Ma, X. Wu, F. Huo, F. Cheng and C. Yin, Chem. Sci., 2022, 13, 218 RSC.
  3. K. L. Obydennov, L. A. Khamidullina, A. N. Galushchinskiy, S. A. Shatunova, M. F. Kosterina, T. A. Kalinina, Z. Fan, T. V. Glukhareva and Y. Yu. Morzherin, J. Agric. Food Chem., 2018, 66, 6239 CrossRef CAS.
  4. L. L. Remsing Rix, B. M. Kuenzi, Y. Luo, E. Remily-Wood, F. Kinose, G. Wright, J. Li, J. M. Koomen, E. B. Haura, H. R. Lawrence and U. Rix, ACS Chem. Biol., 2014, 9, 353 CrossRef CAS PubMed.
  5. (a) M. Tabart, G. Picaut, M. Lavergne, S. Wentzler, J. L. Malleron, S. Dutka-Malen and N. Berthaud, Bioorg. Med. Chem. Lett., 2003, 13, 1329 CrossRef CAS PubMed; (b) M. Tabart, G. Picaut, J. F. Desconclois, S. Dutka-Malen, Y. Huet and N. Berthaud, Bioorg. Med. Chem. Lett., 2001, 11, 919 CrossRef CAS.
  6. M. Pand, P.-W. Phuan and M. Kozlowski, J. Org. Chem., 2003, 68, 564 CrossRef PubMed.
  7. (a) R. Morphy, C. Kay and Z. Rankovic, Drug Discovery Today, 2004, 9, 641 CrossRef CAS PubMed; (b) H.-Y. Zhang, D.-P. Yang and G.-Y. Tang, Drug Discovery Today, 2006, 11, 749 CrossRef CAS; (c) D. Duarte, J. Barreiro and A. Fraga, Mini-Rev. Med. Chem., 2007, 7, 1108 CrossRef; (d) A. Talevi, Front. Pharmacol., 2015, 6, 205 Search PubMed; (e) R. Pagliero, M. Kaiser, R. Brun, M. Nieto and M. Mazzieri, Bioorg. Med. Chem. Lett., 2017, 27, 3945 CrossRef CAS; (f) W. Luo, B. Shao, J. Li, X. Xiao, D. Song, F. Ling and W. Zhong, Org. Chem. Front., 2020, 7, 1016 RSC; (g) S. Oh and S. B. Park, Chem. Commun., 2011, 47, 12754 RSC; (h) B.-K. Zhu, H. Xu, L. Xiao, X. Chang, L. Wei, H. Teng, Y. Dang, X.-Q. Dong and C.-J. Wang, Chem. Sci., 2023, 14, 4134 RSC.
  8. For selected examples, see: (a) G. S. Skinner and J. F. Perkins Jr, J. Am. Chem. Soc., 1950, 72, 5569 CrossRef CAS; (b) Y. Dong, Y. Guo, J. Liu, G. Zheng and M. Wang, Eur. J. Org Chem., 2014, 797 CrossRef CAS; (c) S. S. Acharya, S. Patra, R. Maharana, M. Dash, L. M. Barad and B. B. Parida, Org. Biomol. Chem., 2024, 22, 2916 RSC; (d) M. Xiang, C.-Y. Li, J. Zhang, Y. Zou, W.-S. Li, F. Tian, W.-J. Wan and L.-X. Wang, Org. Chem. Front., 2021, 8, 6215 RSC; (e) M. Xiang, C.-Y. Li, X.-J. Song, Y. Zou, Z.-C. Huang, X. Li, F. Tian and L.-X. Wang, Chem. Commun., 2020, 56, 14825 RSC; (f) S. A. Lakatosh, Y. N. Luzikov and M. N. Preobrazhenskaya, Org. Biomol. Chem., 2003, 1, 826 RSC; (g) X. Zhang, K. Pham, S. Liu, M. Legris, A. Muthengi, J. P. Jasinski and W. Zhang, Beilstein J. Org. Chem., 2016, 12, 2204 CrossRef CAS PubMed; (h) P. S. Vargas, F. A. Rosa, L. Buriol, M. Rotta, D. N. Moreira, C. P. Frizzo, H. G. Bonacorso, N. Zanatta and M. A. P. Martins, Tetrahedron Lett., 2012, 53, 3131 CrossRef CAS; (i) F. Wang, Z. Zhang, Y. Chen, V. Ratovelomanana-Vidal, P. Yu, G.-Q. Chen and X. Zhang, Nat. Commun., 2022, 13, 7794 CrossRef CAS PubMed.
  9. For selected examples, see: (a) H. Hassan, S. Mohammed, F. Robert and Y. Landais, Org. Lett., 2015, 17, 4518 CrossRef CAS PubMed; (b) R. X. Yi, X. C. Li and B. S. Wan, Adv. Synth. Catal., 2018, 360, 875 CrossRef CAS; (c) M. T. Rodrigues, J. C. Gomes, J. Smith and F. Coelho, Tetrahedron Lett., 2010, 51, 4988 CrossRef CAS; (d) L. Smith and A. S. Kiselyov, Tetrahedron Lett., 1999, 40, 5643 CrossRef CAS; (e) L. R. Wen, C. Liu, M. Li and L. J. Wang, J. Org. Chem., 2010, 75, 7605 CrossRef CAS PubMed; (f) K. Tateno, R. Ogawa, R. Sakamoto, M. Tsuchiya, N. Kutsumura, T. Otani, K. Ono, H. Kawai and T. Saito, J. Org. Chem., 2018, 83, 690 CrossRef CAS PubMed; (g) A. Weyesa and E. Mulugeta, RSC Adv., 2020, 10, 20784 RSC; (h) S. Oh and S. B. Park, Chem. Commun., 2011, 47, 12754 RSC; (i) J. A. Bull, J. J. Mousseau, G. Pelletier and A. B. Charette, Chem. Rev., 2012, 112, 2642 CrossRef CAS PubMed; (j) M. Edrisi and N. Azizi, J. Iran. Chem. Soc., 2020, 17, 901 CrossRef CAS; (k) N. Azizi, A. Mobinikhaledi, A. K. Amiri and H. Ghafuri, Res. Chem. Intermed., 2012, 38, 2271 CrossRef CAS; (l) J. Yu, F. Shi and L. Z. Gong, Acc. Chem. Res., 2011, 44, 1156 CrossRef CAS PubMed; (m) S. Ko, M. Sastry, C. Lin and C. F. Yao, Tetrahedron Lett., 2005, 46, 57718 CrossRef.
  10. For selected examples, see: (a) H. Mu, Y. Jin, R. Zhao, L. Wang and Y. Jin, Molecules, 2022, 27, 7787 CrossRef CAS; (b) X. Gao, L. Tang, L. Huang, Z.-S. Huang, Y. Ma and G. Wu, Org. Lett., 2019, 21, 745 CrossRef CAS PubMed; (c) S. Huang, Q. Yang, J. Wan, Z. Wang, Z. Zhang, T. Liu and C. Huang, Adv. Synth. Catal., 2023, 365, 2588 CrossRef CAS; (d) F. Yuan, W. Duan, Z. Li, X. Luo, M. Zhang, H. Deng and L. Song, Synthesis, 2019, 51, 3345 CrossRef CAS; (e) E. Taheri and F. Jafarpour, Org. Biomol. Chem., 2024, 22, 169 RSC.
  11. For selected examples, see: (a) S. V. Chepyshev, Y. N. Mazurkevich, O. S. Lebed and A. V. Prosyanik, Chem. Heterocycl. Compd., 2007, 43, 844–849 CrossRef CAS; (b) S. Huang, T. Liu, J. Li, Q. Yang, S. Zhan and C. Huang, Synthesis, 2023, 55, 1441 CrossRef CAS; (c) X. Zhang, K. Pham, S. Liu, M. Legris, A. Muthengi, J. P. Jasinski and W. Zhang, Beilstein J. Org. Chem., 2016, 12, 2204 CrossRef CAS PubMed.
  12. (a) Q. Yang, S. Huang, L. Yin, Z. Wang, X. Chen and C. Huang, Org. Biomol. Chem., 2023, 21, 6039 RSC; (b) S. Barik, R. Chandra Das, K. Balanna and A. T. Biju, Org. Lett., 2022, 24, 5456 CrossRef CAS PubMed; (c) G. Yin, Y. Zhu, N. Wang, P. Lu and Y. Wang, Tetrahedron, 2013, 69, 8353 CrossRef CAS; (d) Z. Wang, S. Huang, L. Yin, J. Wan, C. Liu, T. Liu and C. Huang, J. Org. Chem., 2024, 89, 5498 CrossRef CAS; (e) Q. Yang, S. Huang, L. Yin, Z. Wang, X. Chen and C. Huang, Org. Biomol. Chem., 2023, 21, 6039 RSC; (f) A. Alizadeh and A. Rostampoor, Org. Biomol. Chem., 2023, 21, 6160 RSC; (g) Y. Chu, M. Wu, F. Hu, P. Zhou, Z. Cao and X.-P. Hui, Org. Lett., 2022, 24(21), 3884 CrossRef CAS PubMed; (h) L.-N. Pan, J. Sun, X.-Y. Liu and C.-G. Yan, Org. Biomol. Chem., 2022, 20, 7099 RSC; (i) D.-H. Tuo, Q. He, Q.-Q. Wang, Y.-F. Ao and D.-X. Wang, Chin. J. Chem., 2019, 37, 684 CrossRef CAS; (j) M. Xiao and C. Yan, Chin. J. Chem., 2017, 35, 1422–1430 CrossRef CAS; (k) X. Zhang, G. Dhawan, A. Muthengi, S. Liu, W. Wang, M. Legrisa and W. Zhang, Green Chem., 2017, 19, 3851 RSC.
  13. (a) J. Clayden and S. Warren, Solutions Manual to Accompany Organic Chemistry Caption 6: Nucleophilic Addition to the Carbonyl Group, Oxford University Press, 2012 Search PubMed; (b) S. Zhang, M. D. Greenhalgh, A. M. Z. Slawin and A. D. Smith, Chem. Sci., 2020, 11, 3885 RSC; (c) A. J. Nimmo, J. Bitai, C. M. Young, C. McLaughlin, A. M. Z. Slawin, D. B. Cordes and A. D. Smith, Chem. Sci., 2023, 14, 7537 RSC.
  14. For selected examples, see: (a) D. Kumar and M. K. Kaushik, Russ. J. Org. Chem., 2023, 59, 1059 CrossRef CAS; (b) S. Dharani, G. Kalaiarasi, V. M. Lynch, K. Srinivasan and R. Prabhakaran, React. Chem. Eng., 2023, 8, 164 RSC; (c) C. Niu and D. M. Du, Org. Biomol. Chem., 2022, 20, 840 RSC.
  15. For selected examples, see: (a) M. M. A. Ali, G. U. Suriyan, K. J. Surya and K. S. Mani, J. Heterocycl. Chem., 2023, 60, 1558 CrossRef CAS; (b) B. Rakesh, P. Divya, R. KVN, V. Muripiti and A. Velidandi, Russ. J. Bioorg. Chem., 2023, 49, 76 CrossRef; (c) S. T. Kolla, R. Somanaboina and C. R. Bhimapaka, Synth. Commun., 2021, 51, 1425 CrossRef CAS; (d) K. S. Mani, W. Kaminsky and S. P. Rajendran, New J. Chem., 2018, 42, 301 RSC; (e) K. S. Mani and S. P. Rajendran, Synth. Commun., 2018, 48, 1324 CrossRef.
  16. For selected examples, see: (a) A. Alizadeh and A. Rostampoor, J. Iran. Chem. Soc., 2022, 19, 1239 CrossRef CAS; (b) X. Xiao, B. Shao, J. Li, Z. Yang, Y. J. Lu, F. Ling and W. Zhong, Chem. Commun., 2021, 57, 4690 RSC; (c) J. Fang, J. Fang, Y. Rao, H. Qiu, Z. Pan and Y. Ma, Org. Biomol. Chem., 2024, 22, 2043 RSC.
  17. (a) W. Luo, X. Zheng, F. Zhang, Q. Luo, W. Deng, L. Long, D. Yu, Z.-X. Wang and Z. Chen, Org. Biomol. Chem., 2023, 21, 9524 RSC; (b) L. Long, X. Li, M. Tu, Y. Zhang, L. Qiao, W. Luo and Z. Chen, Org. Chem. Front., 2023, 10, 473 RSC; (c) L. Long, J. Wang, X. Li, S. Peng, L. Qiao, G. Luo and Z. Chen, Org. Chem. Front., 2022, 9, 2412 RSC; (d) C. Lu, M. Ye, M. Li, Z. Zhang, Y. He, L. Long and Z. Chen, Chin. Chem. Lett., 2021, 32, 3967 CrossRef CAS.
  18. (a) Y. Xue and G. Dong, Acc. Chem. Res., 2022, 55, 2341 CrossRef CAS PubMed; (b) R. Zhao and L. Shi, Angew. Chem., Int. Ed., 2020, 59, 12282 CrossRef CAS PubMed; (c) C. M. B. K. Kourra and N. Cramer, Chem. Sci., 2016, 7, 7007 RSC; (d) I. Alahyen, L. Benhamou, V. Dalla, C. Taillier and S. Comesse, Synthesis, 2021, 53, 3409 CrossRef CAS; (e) M. Kissane and A. R. Maguire, Chem. Soc. Rev., 2010, 39, 845 RSC; (f) H. Hagiwara, Nat. Prod. Commun., 2021, 16, 1 CrossRef; (g) W.-X. Wei, X. Kong, R.-Q. Jiao, X.-S. Li, C.-T. Wang, Y. Li and Y.-M. Liang, Chem. Sci., 2022, 13, 6348 RSC; (h) F.-R. Huang, Q.-J. Yao, P. Zhang, M.-Y. Teng, J.-H. Chen, L.-C. Jiang and B.-F. Shi, J. Am. Chem. Soc., 2024, 146, 15576 CrossRef CAS PubMed; (i) M. Shankar, A. Saha, S. Sau, A. Ghosh, V. Gandon and A. K. Sahoo, Chem. Sci., 2021, 12, 6393 RSC; (j) H. Mamataj Begam, S. Nandi and R. Jana, Chem. Sci., 2022, 13, 5726 RSC.
  19. (a) P.-h. Chen, B. A. Billett, T. Tsukamoto and G. Dong, ACS Catal., 2017, 7, 1340 CrossRef CAS PubMed; (b) K. Wang, C. Jiang, Z. Zhang, C. Han, X. Wang, Y. Li, K. Chen and J. Zhao, Chem. Commun., 2020, 56, 12817 RSC; (c) M. Cao, Y. Ren, R. Zhang, H. Xu, P. Cheng, H. Xu, Y. Xu and P. Li, Org. Lett., 2023, 25, 6300 CrossRef CAS PubMed; (d) Y. Wang, B. Qiu, L. Hu, G. Lu and T. Xu, ACS Catal., 2021, 11, 9136 CrossRef CAS; (e) L.-F. Tao, F. Huang, X. Zhao, L. Qian and J.-Y. Liao, Cell Rep. Phys. Sci., 2023, 4, 101697 CrossRef CAS; (f) M. Wu, Z. Han, H. Ni, N. Wang, K. Ding and Y. Lu, Chem. Sci., 2022, 13, 3161 RSC; (g) M. Ma, J. Feng, W. Cai and Y. Huang, Org. Lett., 2024, 26, 4037 CrossRef CAS PubMed; (h) Y. Liu, R. Wang, Q. Zheng, X. Hu, F. Liu and N. Yan, Org. Chem. Front., 2024, 11, 2047 RSC; (i) H. Huang, Y. Jiang, W. Yuan and Y.-M. Lin, Angew. Chem., Int. Ed., 2024, 63, e202409653 CAS; (j) P. Chen, J. Nan, Y. Hu, Y. Kang, B. Wang, Y. Ma and M. Szostak, Chem. Sci., 2021, 12, 803 RSC.
  20. CCDC 2390992 contains the supplementary crystallographic data for this paper.
  21. Q. Wang, L. Fu, Z. Gao, J. Huang, L. Zhang, H. Wang, Y. Zhong, M. Zhou, Q. Huang and M. Yang, Mol. Catal., 2024, 565, 114405 CrossRef CAS.
  22. C. He, H. Wang, L. Fu, Q. Wang, Y. Zhong, M. Zeng, X. Lin, J. Huang, J. Xie, Q. Huang and M. Yang, Dyes Pigm., 2024, 228, 112252 CrossRef CAS.
  23. C. He, Q. Wang, X. Zhou, L. Yi, Z. Zhang, C. Zhang, H. Xie, Q. Huang, G. Qiu and M. Yang, J. Org. Chem., 2024, 89, 3509 CrossRef CAS PubMed.
  24. Q. Wang, L. Fu, Y. Zhong, L. Xu, L. Yi, C. He, Y. Kuang, Q. Huang and M. Yang, Talanta, 2024, 272, 125766 CrossRef CAS PubMed.
  25. Y. Wu, W. Lun, H. Zeng, X. Guo, M. Yang and Q. Lan, Anal. Chim. Acta, 2024, 1294, 342292 CrossRef CAS PubMed.
  26. H. Han, Y. Zhong, C. He, L. Fu, Q. Huang, Y. Kuang, X. Yi, W. Zeng, H. Zhong and M. Yang, Dyes Pigm., 2022, 204, 110386 CrossRef CAS.
  27. C. He, Y. Zhong, H. Han, Q. Wang, L. Xu, T. Zhang, Y. Hu, Q. Huang, J. Liu and M. Yang, New J. Chem., 2022, 46, 21032 RSC.
  28. M. Yang, J. Chen, C. He, X. Hu, Y. Ding, Y. Kuang, J. Liu and Q. Huang, J. Org. Chem., 2020, 85, 6498 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available: Synthetic details, spectroscopic characterization and crystallographic data. CCDC 2390992. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d4sc07999j

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.